Socazolimab clinical trials
How each study uses socazolimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the socazolimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2018 | 3 |
| 2020 | 1 |
| 2021 | 3 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test socazolimab, phase 3 first.
- Sep 2027Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical CancerPhase 3 · Lee's Pharmaceutical Limited
Studies
Open first, then newest update. How each study uses socazolimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical CancerRecruitingPhase 3Lee's Pharmaceutical LimitedNCT06459687Written as Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab
- A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLCCompletedPhase 3Lee's Pharmaceutical LimitedNCT04878016Written as ZKAB001
- Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic MelanomaStatus unknownPhase 1/2Lee's Pharmaceutical LimitedNCT04849260Written as Pexa-Vec combined with ZKAB001
- A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract CancerStatus unknownPhase 1Lee's Pharmaceutical LimitedNCT04608786Written as ZKAB001 5mg/kg
- A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Recurrent or Metastatic Cervical CancerStatus unknownPhase 1Lee's Pharmaceutical LimitedNCT03676959Written as ZKAB001 5mg/kg
- Study of ZKAB001 for Maintenance Therapy in Patients With High-grade Osteosarcoma After Adjuvant ChemotherapyStatus unknownPhase 3Lee's Pharmaceutical LimitedNCT04359550Written as Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)
- A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial CarcinomaStatus unknownPhase 1/2Lee's Pharmaceutical LimitedNCT03676946Written as ZKAB001 5mg/kg
- A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of High-grade OsteosarcomaStatus unknownPhase 1/2Lee's Pharmaceutical LimitedNCT03676985Written as ZKAB001 5mg/kg
Codes
What other systems call socazolimab · ClinicalTrials.gg INT015582
- UNII (FDA) 82P4S8Q3FBSOCAZOLIMABOne source FDA
- NCI Thesaurus C162504SocazolimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 82P4S8Q3FB | SOCAZOLIMAB | One source FDA |
| NCI Thesaurus | C162504 | Socazolimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.